Adding Talazoparib to Enzalutamide Prolongs Imaging-Based PFS in Metastatic Androgen Pathway Modulation-Sensitive Prostate Cancer with Alterations in HRR Genes By Ogkologos - June 15, 2026 175 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-3 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL Meet the first recipient of the ESMO Artificial Intelligence Fellowship MOST POPULAR Nurse With Terminal Breast Cancer Spends Her Days Caring For Pediatric... April 14, 2020 EMA Recommends Extension of Therapeutic Indications for Ibrutinib July 15, 2022 The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights... December 22, 2025 Similarity of Molecular Portraits in Synchronous Bilateral Breast Cancers Could be... March 22, 2023 Load more HOT NEWS Invasive Lobular Carcinoma Is Invisible On Mammograms, Isn’t A Lump FDA Approves Dostarlimab-gxly with Chemotherapy for Endometrial Cancer Opinion: ‘The idea that a tobacco company might profit off my... Interpreted cancer awareness workshops: talking about cancer with South-Asian communities
